RECORD // Company

Yarrow Bioscience, Inc.

Formerly: VYNE Therapeutics Inc.; Menlo Therapeutics Inc.; Menlo Therapeutics, Inc.; Tigercat Pharma, Inc.

Built 2026-11-22T02:59:06Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (1)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • YARROW BIOSCIENCE, INC. · Ct business · same registered legal name as 'Yarrow Bioscience, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Yarrow Bioscience, Inc. · Ctgov · same registered legal name as 'Yarrow Bioscience, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001566044-26-000019

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-9,724,0003 months ended 2026-09-3010-Q2026-11-130001566044-26-0000192026-11-22 02:59 UTCReport an error
Cash and cash equivalents$268,860,000at 2026-09-3010-Q2026-11-130001566044-26-0000192026-11-22 02:59 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001566044
Ticker
YARW
EIN
453757789
CUSIP
92941V407
Record ID
sx:sec:0001566044

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

25 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-22 02:59 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-20SEC EDGAR company profile2026-11-22 02:59 UTCReport an error
State of incorporationDE2026-11-20SEC EDGAR company profile2026-11-22 02:59 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-22 02:59 UTCReport an error
Business address470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 065132026-11-20SEC EDGAR company profile2026-11-22 02:59 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-22 02:59 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$570,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 02:59 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-26,483,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 02:59 UTCReport an error
Total assets (at 2025-12-31)$30,160,0002025-12-3110-K, XBRL Assets2026-11-22 02:59 UTCReport an error
Stockholders' equity (at 2025-12-31)$27,765,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 02:59 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$24,027,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 02:59 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-33,124,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 02:59 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL PaymentsToAcquireProductiveAssets2026-11-22 02:59 UTCReport an error
Long-term debt (at 2025-12-31)$02025-12-3110-K, XBRL LongTermDebt2026-11-22 02:59 UTCReport an error
Operating lease liabilities (at 2024-12-31)$99,0002024-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 02:59 UTCReport an error
Form D total offering amount (D filed 2023-11-16)$88,151,5082023-11-16D2026-11-22 02:59 UTCReport an error
Form D total amount sold (D filed 2023-11-16)$88,151,5082023-11-16D2026-11-22 02:59 UTCReport an error
Form D industry groupBiotechnology2023-11-16D2026-11-22 02:59 UTCReport an error
Form D revenue rangeDecline to Disclose2023-11-16D2026-11-22 02:59 UTCReport an error
Form D date of first sale2023-11-012023-11-16D2026-11-22 02:59 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12)On November 12, 2026, Yarrow Bioscience, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The press release is being furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in…2026-11-12SEC EDGAR 8-K 0001566044-26-000017 (text as filed, excerpt)2026-11-22 02:59 UTCReport an error
8-K Item 1.01 (filed 2026-09-14)Entry into a Material Definitive Agreement. On September 10, 2026, Yarrow Bioscience, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 5,769,231 shares of the Company’s common stock at a public offering price of $26.00 per share (the “Offering”). In addition, the Company has granted the Underwriters an option (the “Option”) for a period of 30 days to purchase up to an additional 865,384 shares of its common stock at the public offering price, less the underwriting discounts and…2026-09-14SEC EDGAR 8-K 0001104659-26-107485 (text as filed, excerpt)2026-11-22 02:59 UTCReport an error
8-K Item 8.01 (filed 2026-09-10)Other Events. Corporate Presentation On September 10, 2026, Yarrow Bioscience, Inc., a Delaware corporation (the “Company”), made available the Company’s investor presentation to be used in general corporate communications and investor communications. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Update to Part I, Item 1 – Business of the Annual Report This Current Report on Form 8-K updates Part I, Item 1 – Business of the Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) of the Company to reflect the merger between the Company and Yarrow Bioscience Operating…2026-09-10SEC EDGAR 8-K 0001104659-26-106699 (text as filed, excerpt)2026-11-22 02:59 UTCReport an error
8-K Item 2.02 (filed 2026-08-13)Results of Operations and Financial Condition. This Amendment No. 1 includes (i) the financial statements of Pre-Merger Yarrow as of and for the three and six months ended June 30, 2026, (ii) the financial statements of Pre-Merger Yarrow as of December 31, 2025 and October 3, 2025, and for the period from October 3, 2025 (inception) to December 31, 2025, which have been recast to give retroactive effect to the Exchange Ratio, (iii) Pre-Merger Yarrow’s Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the three and six months ended June 30, 2026, and (iv) the unaudited pro forma condensed combined balance sheet of the Company and Pre-Merger…2026-08-13SEC EDGAR 8-K 0001104659-26-095925 (text as filed, excerpt)2026-11-22 02:59 UTCReport an error
8-K Item 7.01 (filed 2026-08-13)Regulation FD Disclosure. On August 13, 2026, the Company made available an updated corporate presentation on the Company’s website. A copy of the corporate presentation is furnished as Exhibit 99.8 to this Amendment No. 1 and is incorporated herein by reference. This Item 7.01 and Exhibit 99.8 to this Amendment No. 1 are being furnished to the SEC and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.2026-08-13SEC EDGAR 8-K 0001104659-26-095925 (text as filed, excerpt)2026-11-22 02:59 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.